ARTICLE | Clinical News
MIN-102: Ph I data
April 12, 2017 12:33 AM UTC
A double-blind, placebo-controlled, Dutch Phase I trial in healthy male volunteers showed that single and multiple ascending doses of MIN-102 were generally well tolerated with no serious adverse even...
BCIQ Company Profiles
BCIQ Target Profiles